JAC Advance Access published online on November 18, 2002
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkf249
© 2002 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Paper
1 The JONES Group/JMI Laboratories,
345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317; ; Tufts University School of Medicine,
Boston, MA, USA
* Corresponding author. E-mail: ronald-jones{at}jmilabs.com.
Received 10 May 2002
; revised 29 July 2002
; accepted 9 September 2002
Community-acquired and nosocomial infections caused
by multidrug-resistant Gram-positive pathogens continue to increase
in prevalence and have become a serious problem in many parts of
the world. BAL9141 is a member of the class of parenteral pyrrolidinone-3-ylidenemethyl cephalosporins,
and has a broad spectrum of activity. In the current study, BAL9141
was tested against a large number (n = 2263)
of recent isolates from various international surveillance programmes
including 1097 Gram-positive strains. Susceptibility to (S) and
activity of (mg/L) to BAL9141, based on proposed breakpoints (MIC50/MIC90/% S)
were as follows: methicillin-susceptible Staphylococcus
aureus (0.5/0.5/100%), methicillin-resistant S.
aureus (MRSA) (1/2/100%), methicillin-susceptible
coagulase-negative staphylococci (CoNS) (0.12/0.25/100%), methicillin-resistant
CoNS (MR-CoNS) (1/2/100%), Streptococcus pneumoniae (
Keywords: BAL9141, parenteral cephalosporin, MRSA, antimicrobial
activity, resistance
In vitro evaluation of BAL9141,
a novel parenteral cephalosporin active against oxacillin-resistant
staphylococci
2 The JONES Group/JMI Laboratories,
345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
0.015/0.25/100%), viridans
group streptococci (0.03/0.5/99%), 
-haemolytic
streptococci (0.015/0.015/100%), Enterococcus faecalis (0.5/16/90%), Enterococcus faecium (>32/>32/22%), Haemophilus influenzae (0.06/0.06/100%), Moraxella catarrhalis (0.06/0.5/100%), Neisseria gonorrhoeae (0.03/0.06/100%)
and Neisseria meningitidis (0.002/0.004/100%).
BAL9141 susceptibility at 4
mg/L (100% S) surpassed that of ceftriaxone (CRO; 1% S)
and quinupristin/dalfopristin (Q-D; 92% S) against MRSA
and MR-CoNS (CRO 0.9% S; Q-D 94% S). All S.
pneumoniae were inhibited by BAL9141 at 1
mg/L compared with CRO (90% S) and levofloxacin (LVX; 98% S).
Susceptibility rates for viridans group streptococci to BAL9141
(>98%) were also higher than to CRO (86%)
and LVX (96%). BAL9141 demonstrated excellent activity
against most species of wild-type enteric bacilli, with 
95% of
isolates being susceptible; however, only modest activity was observed
for BAL9141 against non-fermentative Gram-negative species and ESBL-producing Escherichia coli or Klebsiella pneumoniae.
BAL9141 demonstrated excellent activity against many tested pathogens
displaying various resistance phenotypes, and should be particularly
valuable in the treatment of MRSA as well as for drug-resistant
streptococci, while maintaining a spectrum resembling a ‘third-generation' cephalosporin
against other clinically important species.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Barbour, S. Schmidt, S. N. Sabarinath, M. Grant, C. Seubert, D. Skee, B. Murthy, and H. Derendorf Soft-Tissue Penetration of Ceftobiprole in Healthy Volunteers Determined by In Vivo Microdialysis Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2773 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Craig and D. R. Andes In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3492 - 3496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Amsler, T. A. Davies, W. Shang, M. R. Jacobs, and K. Bush In Vitro Activity of Ceftobiprole against Pathogens from Two Phase 3 Clinical Trials of Complicated Skin and Skin Structure Infections Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3418 - 3423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Leonard, C. M. Cheung, and M. J. Rybak Activities of Ceftobiprole, Linezolid, Vancomycin, and Daptomycin against Community-Associated and Hospital-Associated Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2974 - 2976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-C. Hsieh, K.-Y. Chang, Y.-C. Huang, H.-C. Lin, Y.-H. Ho, L.-M. Huang, and P.-R. Hsueh Clonal Spread of Highly {beta}-Lactam-Resistant Streptococcus pneumoniae Isolates in Taiwan Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2266 - 2269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D Anderson and J. G Gums Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin Ann. Pharmacother., June 1, 2008; 42(6): 806 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Pillar, M. K. Aranza, D. Shah, and D. F. Sahm In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin J. Antimicrob. Chemother., March 1, 2008; 61(3): 595 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Thamlikitkul and S. Trakulsomboon In vitro activity of ceftobiprole against Burkholderia pseudomallei J. Antimicrob. Chemother., February 1, 2008; 61(2): 460 - 461. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Noel, R. S. Strauss, K. Amsler, M. Heep, R. Pypstra, and J. S. Solomkin Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria Antimicrob. Agents Chemother., January 1, 2008; 52(1): 37 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Queenan, W. Shang, M. Kania, M. G. P. Page, and K. Bush Interactions of Ceftobiprole with {beta}-Lactamases from Molecular Classes A to D Antimicrob. Agents Chemother., September 1, 2007; 51(9): 3089 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mushtaq, M. Warner, Y. Ge, K. Kaniga, and D. M. Livermore In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes J. Antimicrob. Chemother., August 1, 2007; 60(2): 300 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. Lodise Jr., R. Pypstra, J. B. Kahn, B. P. Murthy, H. C. Kimko, K. Bush, G. J. Noel, and G. L. Drusano Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2378 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Davies, M. G. P. Page, W. Shang, T. Andrew, M. Kania, and K. Bush Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2621 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Jeffres, W. Isakow, J. A. Doherty, P. S. McKinnon, D. J. Ritchie, S. T. Micek, and M. H. Kollef Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care-Associated Pneumonia: Specific Evaluation of Vancomycin Pharmacokinetic Indices. Chest, October 1, 2006; 130(4): 947 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Davies, W. Shang, and K. Bush Activities of Ceftobiprole and Other {beta}-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2530 - 2532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bogdanovich, C. Clark, L. Ednie, G. Lin, K. Smith, S. Shapiro, and P. C. Appelbaum Activities of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2050 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, T. R. Fritsche, Y. Ge, K. Kaniga, and H. S. Sader Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests J. Antimicrob. Chemother., December 1, 2005; 56(6): 1047 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bogdanovich, L. M. Ednie, S. Shapiro, and P. C. Appelbaum Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4210 - 4219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. von Eiff, A. W. Friedrich, K. Becker, and G. Peters Comparative In Vitro Activity of Ceftobiprole against Staphylococci Displaying Normal and Small-Colony Variant Phenotypes Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4372 - 4374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Vaudaux, A. Gjinovci, M. Bento, D. Li, J. Schrenzel, and D. P. Lew Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3789 - 3793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Sader, T. R. Fritsche, K. Kaniga, Y. Ge, and R. N. Jones Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3501 - 3512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosowska, D. B. Hoellman, G. Lin, C. Clark, K. Credito, P. McGhee, B. Dewasse, B. Bozdogan, S. Shapiro, and P. C. Appelbaum Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1932 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schmitt-Hoffmann, B. Roos, M. Schleimer, J. Sauer, A. Man, N. Nashed, T. Brown, A. Perez, E. Weidekamm, and P. Kovacs Single-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2570 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schmitt-Hoffmann, L. Nyman, B. Roos, M. Schleimer, J. Sauer, N. Nashed, T. Brown, A. Man, and E. Weidekamm Multiple-Dose Pharmacokinetics and Safety of a Novel Broad-Spectrum Cephalosporin (BAL5788) in Healthy Volunteers Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2576 - 2580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Huang, W. J. Brown, and M. J. Rybak In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2719 - 2723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Anderegg, R. N. Jones, and H. S. Sader Quality Control Guidelines for BAL9141 (Ro 63-9141), an Investigational Cephalosporin, When Reference MIC and Standardized Disk Diffusion Susceptibility Test Methods Are Used J. Clin. Microbiol., July 1, 2004; 42(7): 3356 - 3358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Mouton, A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt Use of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141 Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1713 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Bernard, P. Hoffmeyer, M. Assal, P. Vaudaux, J. Schrenzel, and D. Lew Reply J. Antimicrob. Chemother., May 1, 2004; 53(5): 887 - 887. [Full Text] [PDF]
|
|
|
|
|
|
E. Azoulay-Dupuis, J. P. Bedos, J. Mohler, A. Schmitt-Hoffmann, M. Schleimer, and S. Shapiro Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal Pneumonia Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1105 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Sader, D. M. Johnson, and R. N. Jones In Vitro Activities of the Novel Cephalosporin LB 11058 against Multidrug-Resistant Staphylococci and Streptococci Antimicrob. Agents Chemother., January 1, 2004; 48(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Hardy, P. M. Hawkey, F. Gao, and B. A. Oppenheim Methicillin resistant Staphylococcus aureus in the critically ill Br. J. Anaesth., January 1, 2004; 92(1): 121 - 130. [Abstract] [Full Text] [PDF]
|
|